Citadel Advisors »

Sonnet Biotherapeutc Hldng I shares owned by Citadel Advisors

Quarter-by-quarter ownership of Sonnet Biotherapeutc Hldng I (SONN) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Sonnet Biotherapeutc Hldng I

Tip: Access up to 7 years of quarterly data

All positions including Sonnet Biotherapeutc Hldng I held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sonnet Biotherapeutc Hldng I by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $211k 46k 4.58
2024-12-31 $35k 24k 1.46

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Spdr Gold Tr Gold Shs Call Option (GLD)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
Strategy Cl A New Call Option (MSTR)
Alphabet Cap Stk Cl A Call Option (GOOGL)
UnitedHealth Call Option (UNH)
Palantir Technologies Cl A Call Option (PLTR)
Netflix Call Option (NFLX)

View all positions for Citadel Advisors

Top funds holding Sonnet Biotherapeutc Hldng I

Ikarian Capital
Vanguard Group
Hrt Financial
Geode Capital Management
Boothbay Fund Management
Goldman Sachs Group
Citadel Advisors
Virtu Financial
State Street Corporation
BlackRock
Northern Trust
Two Sigma Investments
Investment House
Jane Street
Jpmorgan Chase & Co

View all funds holding Sonnet Biotherapeutc Hldng I